Employees: 03 (2023.0)Legal category: SCA (commandite par actions)Size: PMECreation date: 2014-08-01 (11 years)Status: ActiveBusiness sector: Autres intermédiaires du commerce en produits diversLocation: DIEMOZ (38790), Isere
BIOPHARMA TECHNOLOGIES FRANCE : revenue, balance sheet and financial ratios
BIOPHARMA TECHNOLOGIES FRANCE is a French company
founded 11 years ago,
specialized in the sector Autres intermédiaires du commerce en produits divers.
Based in DIEMOZ (38790),
this company of category PME
shows in 2019 a revenue of 2.0 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - BIOPHARMA TECHNOLOGIES FRANCE (SIREN 803882687)
Indicator
2024
2021
2020
2019
2018
2017
2016
2015
Revenue
N/C
N/C
N/C
2 047 082 €
N/C
1 173 754 €
1 200 799 €
1 360 919 €
Net income
-99 497 €
59 379 €
-13 019 €
94 406 €
7 157 €
37 629 €
-2 900 €
42 021 €
EBITDA
N/C
N/C
N/C
147 186 €
N/C
91 478 €
13 763 €
71 024 €
Net margin
N/C
N/C
N/C
4.6%
N/C
3.2%
-0.2%
3.1%
Revenue and income statement
In 2024, BIOPHARMA TECHNOLOGIES FRANCE records a net loss of 99 k€. This deficit will reduce equity on the balance sheet.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
-99 497 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 69%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
0.0%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
69.148%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution BIOPHARMA TECHNOLOGIES FRANCE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2015
2016
2017
2018
2019
2020
2021
2024
Debt ratio
17.092
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Financial autonomy
21.966
37.138
47.432
14.697
36.66
39.665
35.808
69.148
Repayment capacity
0.562
0.0
0.0
None
0.0
None
None
None
Cash flow / Revenue
3.173%
-0.242%
6.238%
None%
4.575%
None%
None%
None%
Sector positioning
Debt ratio
0.02024
2020
2021
2024
Q1: 0.0
Med: 6.15
Q3: 45.95
Excellent
In 2024, the debt ratio of BIOPHARMA TECHNOLOGIES FR... (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
69.15%2024
2020
2021
2024
Q1: 3.97%
Med: 34.0%
Q3: 67.32%
Excellent+21 pts over 3 years
In 2024, the financial autonomy of BIOPHARMA TECHNOLOGIES FR... (69.2%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 306.31. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
306.305
Liquidity indicators evolution BIOPHARMA TECHNOLOGIES FRANCE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2015
2016
2017
2018
2019
2020
2021
2024
Liquidity ratio
129.827
150.782
223.588
155.015
154.306
347.315
242.704
306.305
Interest coverage
0.151
68.321
11.671
None
0.981
None
None
None
Sector positioning
Liquidity ratio
306.312024
2020
2021
2024
Q1: 139.4
Med: 252.5
Q3: 584.37
Good-9 pts over 3 years
In 2024, the liquidity ratio of BIOPHARMA TECHNOLOGIES FR... (306.31) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution BIOPHARMA TECHNOLOGIES FRANCE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2015
2016
2017
2018
2019
2020
2021
2024
Operating WCR
235 167 €
145 657 €
24 661 €
0 €
432 323 €
0 €
0 €
0 €
Inventory turnover (days)
2
5
13
0
5
0
0
0
Customer payment term (days)
86
51
24
0
83
0
0
0
Supplier payment term (days)
94
46
29
0
89
0
0
0
Positioning of BIOPHARMA TECHNOLOGIES FRANCE in its sector
Comparison with sector Autres intermédiaires du commerce en produits divers
Similar companies (Autres intermédiaires du commerce en produits divers)
Compare BIOPHARMA TECHNOLOGIES FRANCE with other companies in the same sector:
Frequently asked questions about BIOPHARMA TECHNOLOGIES FRANCE
What is the revenue of BIOPHARMA TECHNOLOGIES FRANCE ?
The revenue of BIOPHARMA TECHNOLOGIES FRANCE in 2019 is 2.0 M€.
Is BIOPHARMA TECHNOLOGIES FRANCE profitable?
BIOPHARMA TECHNOLOGIES FRANCE recorded a net loss in 2024.
Where is the headquarters of BIOPHARMA TECHNOLOGIES FRANCE ?
The headquarters of BIOPHARMA TECHNOLOGIES FRANCE is located in DIEMOZ (38790), in the department Isere.
Where to find the tax return of BIOPHARMA TECHNOLOGIES FRANCE ?
The tax return of BIOPHARMA TECHNOLOGIES FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does BIOPHARMA TECHNOLOGIES FRANCE operate?
BIOPHARMA TECHNOLOGIES FRANCE operates in the sector Autres intermédiaires du commerce en produits divers (NAF code 46.19B). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart